Search Within

Gregory J Riely

  1. "Nursing"
Formats
  1. Journal Article (12)
  2. Meeting Abstract (6)
Groups
  1. Department of Medicine (18)
  2. Nursing (18)
  3. Solid Tumor Oncology Division (18)
  4. Thoracic Oncology (18)
  5. Radiology, Department of (14)
  6. Department of Pathology and Laboratory Medicine (11)

More Groups

People
  1. Mark Kris (16)
  2. Helena Yu (9)
  3. Linda Ahn (8)
  4. Michelle Ginsberg (7)
  5. Marc Ladanyi (6)
  6. Ai Ni (5)

More People

Years
  1. 2024 (2)
  2. 2023 (2)
  3. 2022 (1)
  4. 2021 (1)
  5. 2020 (1)
  6. 2019 (2)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Clinical Cancer Research (3)
  3. Cancer (2)
  4. Cancer Discovery (1)
  5. Cold Spring Harbor Molecular Case Studies (1)
  6. JAMA Oncology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (6)
  2. American Association for Cancer Research (4)
  3. Wiley Blackwell (2)
  4. American Medical Association (1)
  5. Cold Spring Harbor Laboratory Press (1)
  6. Elsevier BV (1)

More Publishers

Results (18)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 2 study of amivantamab plus lazertinib in patients with EGFR-mutant lung cancer and active central nervous system disease
    Meeting Abstract

    Yu, H. A.; Chen, M. F.; Hui, A. B.; Choudhury, N. J.; Lee, J. J. K.; Zheng, J.; Ahn, L. S. H.; Pupo, A.; Nesselbush, M.; Jabara, I.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Optimizing clinical research in a regional cancer center network: A survey-based approach
    Meeting Abstract

    Preeshagul, I. R.; Syldor, A.; Terzulli, S. L.; Gordon, R. A.; Evans, L. A.; Moran, S.; Eng, J.; Daly, R. M.; Rao, D.; Momtaz, P.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Brief report: Combination of osimertinib and dacomitinib to mitigate primary and acquired resistance in EGFR-mutant lung adenocarcinomas
    Journal Article

    Elkrief, A.; Makhnin, A.; Moses, K. A.; Ahn, L. S.; Preeshagul, I. R.; Iqbal, A. N.; Hayes, S. A.; Plodkowski, A. J.; Paik, P. K.; Ladanyi, M.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Molecular characterization of acquired resistance to KRAS(G12C)–EGFR inhibition in colorectal cancer
    Journal Article

    Yaeger, R.; Mezzadra, R.; Sinopoli, J.; Bian, Y.; Marasco, M.; Kaplun, E.; Gao, H.; Zhao, H. Y.; Paula, A. D. C.; Zhu, Y.; more...
    Cancer Discovery (2023)

    Fulltext@MSK | Save
  • Phase 1 clinical trial of trametinib and ponatinib in patients with NSCLC harboring KRAS mutations
    Journal Article

    Arbour, K. C.; Manchado, E.; Bott, M. J.; Ahn, L.; Tobi, Y.; Ni, A. A.; Yu, H. A.; Shannon, A.; Ladanyi, M.; Perron, V.; more...
    JTO Clinical and Research Reports (2022)

    Fulltext@MSK | Save
  • Erlotinib and trametinib in patients with EGFR-mutant lung adenocarcinoma and acquired resistance to a prior tyrosine kinase inhibitor
    Journal Article

    Luo, J.; Makhnin, A.; Tobi, Y.; Ahn, L.; Hayes, S. A.; Iqbal, A.; Ng, K.; Arcila, M. E.; Riely, G. J.; Kris, M. G.; more...
    JCO Precision Oncology (2021)

    Fulltext@MSK | Save
  • Effect of osimertinib and bevacizumab on progression-free survival for patients with metastatic EGFR-mutant lung cancers: A phase 1/2 single-group open-label trial
    Journal Article

    Yu, H. A.; Schoenfeld, A. J.; Makhnin, A.; Kim, R.; Rizvi, H.; Tsui, D.; Falcon, C.; Houck-Loomis, B.; Meng, F.; Yang, J. L.; more...
    JAMA Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1/2 study of osimertinib and bevacizumab as initial treatment for patients with metastatic EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Kim, R.; Makhnin, A.; Ahn, L. S. H.; Ni, A.; Hayes, S. A.; Young, R. J.; Riely, G. J.; Kris, M. G.
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Exceptional responders with invasive mucinous adenocarcinomas: A phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers
    Journal Article

    Drilon, A.; Schoenfeld, A. J.; Arbour, K. C.; Litvak, A.; Ni, A.; Montecalvo, J.; Yu, H. A.; Panora, E.; Ahn, L.; Kennedy, M.; more...
    Cold Spring Harbor Molecular Case Studies (2019)

    Fulltext@MSK | Save
  • Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases
    Journal Article

    Arbour, K. C.; Kris, M. G.; Riely, G. J.; Ni, A.; Beal, K.; Daras, M.; Hayes, S. A.; Young, R. J.; Rodriguez, C. R.; Ahn, L.; more...
    Cancer (2018)

    Fulltext@MSK | Save